LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

Search

ESPERION THERAPEUTICS INC

Cerrado

SectorSalud

1.03 -3.74

Resumen

Variación precio

24h

Actual

Mínimo

0.99

Máximo

1.07

Métricas clave

By Trading Economics

Ingresos

-19M

-40M

Ventas

-4.1M

65M

BPA

-0.206

Margen de beneficio

-62.243

Empleados

304

EBITDA

-16M

-21M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+458.88% upside

Dividendos

By Dow Jones

Próximas Ganancias

11 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

74M

232M

Apertura anterior

4.77

Cierre anterior

1.03

Noticias sobre sentimiento de mercado

By Acuity

49%

51%

131 / 381 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

ESPERION THERAPEUTICS INC Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

20 jun 2025, 18:52 UTC

Ganancias

Accenture Shares Fall on Bookings Decline, Concerns over Federal Government Contract -- 3rd Update

22 jun 2025, 23:59 UTC

Charlas de Mercado

Gold Edges Higher Amid Worries Over Middle East Conflict -- Market Talk

22 jun 2025, 23:55 UTC

Charlas de Mercado

Markets Wait to See if Iran's Response Will be Symbolic or Substantial -- Market Talk

22 jun 2025, 23:51 UTC

Charlas de Mercado

Oil Climbs After U.S. Attack on Iran's Nuclear Sites -- Market Talk

22 jun 2025, 23:43 UTC

Charlas de Mercado

Reasons to Believe Strait of Hormuz Will Remain Open -- Market Talk

22 jun 2025, 23:38 UTC

Charlas de Mercado

Nikkei May Fall as Middle East Uncertainty Persists -- Market Talk

22 jun 2025, 23:11 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 jun 2025, 23:11 UTC

Charlas de Mercado

Early Market Reaction to Iran Attacks Restrained -- Market Talk

22 jun 2025, 22:59 UTC

Charlas de Mercado

Gold, Silver Rise as Investors Seek Haven After Strikes on Iran -- Market Talk

22 jun 2025, 21:43 UTC

Charlas de Mercado

Australian Govt Says Supports US Strikes On Iran -- Market Talk

21 jun 2025, 08:20 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

21 jun 2025, 08:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

21 jun 2025, 08:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

20 jun 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

20 jun 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

20 jun 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

20 jun 2025, 20:13 UTC

Ganancias
Adquisiciones, fusiones, absorciones

These Stocks Moved the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20 jun 2025, 20:11 UTC

Charlas de Mercado

Natural Gas Slides in Late-Week Profit Taking -- Market Talk

20 jun 2025, 19:56 UTC

Charlas de Mercado

Crude Oil Slips to End Week -- Market Talk

20 jun 2025, 18:35 UTC

Charlas de Mercado

Warehouse Clubs Seen Growing Market Share -- Market Talk

20 jun 2025, 18:12 UTC

Charlas de Mercado

Gold Slides to Close Shortened Week -- Market Talk

20 jun 2025, 17:56 UTC

Charlas de Mercado

Baker Hughes Reports Slight Decrease in U.S. Rig Count -- Market Talk

20 jun 2025, 17:50 UTC

Ganancias
Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20 jun 2025, 17:35 UTC

Adquisiciones, fusiones, absorciones

Cisco Was the Dot-Com Bust's Biggest Loser. Now It's at a 25-Year High. -- Barrons.com

20 jun 2025, 17:30 UTC

Charlas de Mercado
Ganancias

Adobe's AI Headwinds Seen Fading -- Market Talk

20 jun 2025, 17:03 UTC

Ganancias

Accenture Earnings Beat Expectations. Why the Stock Is Falling Anyway. -- Barrons.com

20 jun 2025, 16:50 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

20 jun 2025, 16:50 UTC

Charlas de Mercado
Ganancias

Accenture Seeing Companies Shift to Leapfrog Mentality -- Market Talk

20 jun 2025, 16:44 UTC

Adquisiciones, fusiones, absorciones

Meet QXO, the Upstart Building Materials Stock That May Battle Home Depot for GMS -- Barrons.com

20 jun 2025, 16:40 UTC

Charlas de Mercado
Ganancias

Accenture Can't Yet Estimate Longer Term Impact from Federal Cuts -- Market Talk

Comparación entre iguales

Cambio de precio

ESPERION THERAPEUTICS INC Esperado

Precio Objetivo

By TipRanks

458.88% repunte

Estimación a 12 meses

Media 5.98 USD  458.88%

Máximo 16 USD

Mínimo 1.85 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ESPERION THERAPEUTICS INC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

4

Comprar

1

Mantener

1

Vender

Puntuación técnica

By Trading Central

0.85 / 1.05Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

131 / 381 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.